Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Shattuck

Showing results (61-70 of 63) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 63 results.
Journal of Forensic Sciences|February 3, 2022
A comparison of three decalcification agents for assessments of cranial fracture histomorphologyJered B Cornelison, Carolyn V Isaac, Clara J Devota, et al.
Cell Reports|December 21, 2022
BCL-xL inhibition potentiates cancer therapies by redirecting the outcome of p53 activation from senescence to apoptosisVijaya Bharti, Reese Watkins, Amrendra Kumar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2020
Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK InhibitionRebecca L Shattuck-Brandt, Sheau-Chiann Chen, Emily Murray, et al.
Pageof 7

Showing results (61-70 of 63) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 63 results.
Journal of Forensic Sciences|February 3, 2022
A comparison of three decalcification agents for assessments of cranial fracture histomorphologyJered B Cornelison, Carolyn V Isaac, Clara J Devota, et al.
Cell Reports|December 21, 2022
BCL-xL inhibition potentiates cancer therapies by redirecting the outcome of p53 activation from senescence to apoptosisVijaya Bharti, Reese Watkins, Amrendra Kumar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2020
Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK InhibitionRebecca L Shattuck-Brandt, Sheau-Chiann Chen, Emily Murray, et al.
Pageof 7